Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
VIVE.STthis companyVivesto AB	SEK 7.10	-213.25×	58.31×	0×	-211.61×	-100.2%	0.0%	0.0%	0.0%	-27.4%	-25.0%	-0.6%	0.1×	-0.32×	-133.24×	0.22×	0.0%	3	-14.57	2	C
ACTI.STActive Biotech AB	SEK 3.44	-166.06×	111.47×	0×	-170.4×	-98.9%	0.0%	0.0%	0.0%	-67.1%	-65.6%	-0.5%	0.03×	1.76×	0×	4.66×	0.0%	3	4.44	2	C+
ACUC.STAcuCort AB	SEK 0.40	-2.73×	1.12×	103.97×	-1.68×	-33.7%	-2670.0%	-3856.3%	-3812.2%	-41.1%	-41.6%	-34.8%	0×	1.02×	-90.73×	8.08×	0.0%	3	9.81	1	C-
ARCOMA.STArcoma AB	SEK 8.50	20.97×	1.41×	0.8×	4.36×	-14.6%	5.2%	6.6%	3.8%	6.7%	9.3%	12.5%	0×	-2.2×	73.58×	3.49×	0.0%	6	6.68	3	B+
BIOVIC-B.STBiovica International AB (publ)	SEK 0.31	-1.17×	0.95×	6.14×	-0.26×	-1052.3%	-523.5%	-523.5%	-522.1%	-80.9%	-76.5%	-77.0%	0.05×	1.07×	-176.89×	4.3×	0.0%	3	-9.24	2	C
IMMNOV.STImmunovia AB	SEK 0.03	-0.54×	1.21×	114.1×	-0.02×	293.5%	-11606.4%	-11606.4%	-21301.5%	-225.4%	-108.4%	-100.3%	0.01×	0.99×	-1.2×	5.12×	0.0%	1	-42.87	2	C+
Peer median	—	-1.17×	1.21×	6.14×	-0.26×	-33.7%	-523.5%	-523.5%	-522.1%	-67.1%	-65.6%	-34.8%	0.01×	1.02×	-1.2×	4.66×	0.0%	3	4.44	2	—